- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07343999
Estudo EFICAC-TTR: Exercício e Suplementação Nutricional na Amiloidose Cardíaca por Transtirretina (EFICAC-TTR)
Um Estudo Clínico Prospectivo, Randomizado e Multicêntrico sobre o Efeito de um Programa de Exercício Multicomponente Domiciliário Combinado com Suplementação Nutricional em Doentes com Amiloidose Cardíaca por Transtirretina
Transthyretin cardiac amyloidosis (TTR-CA) is a systemic cardiac disease that predominantly affects older adults and is frequently associated with reduced physical capacity, muscle weakness, frailty, and impaired quality of life. Although disease-modifying treatments can slow cardiac disease progression, functional and nutritional impairment remain important unmet clinical needs.
EFICAC-TTR is a prospective, randomized, multicenter study designed to evaluate the effects of a 12-week home-based multicomponent exercise program combined with nutritional supplementation in adults aged 70 years or older with confirmed TTR-CA.
A total of 47 participants were randomized to one of three parallel groups: (1) usual medical care; (2) a home-based multicomponent exercise program plus microcrystalline cellulose control supplementation; or (3) the same exercise program plus creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).
The primary functional outcomes are change in 6-minute walk test distance and handgrip strength from baseline to 12 weeks. Secondary outcomes include body composition, frailty, quality of life, and nutritional and clinical variables. Mechanistic biomarkers are assessed as exploratory outcomes.
The study aims to determine whether combining exercise with nutritional supplementation can improve functional capacity and related health outcomes in older adults with TTR-CA.
Visão geral do estudo
Status
Condições
Descrição detalhada
Participants were randomized to three parallel study groups. The usual-care group continued standard clinical management without a structured exercise program or study supplementation. Participants in the two exercise groups performed the same 12-week home-based multicomponent exercise program adapted to individual functional capacity.
In addition to exercise, one group received daily microcrystalline cellulose as a control supplement, whereas the experimental group received creatine monohydrate (3 g/day) plus beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day). The supplement comparison was blinded, while the comparison with usual care was necessarily open because of the behavioral intervention. Functional outcomes were assessed at baseline and after 12 weeks.
Biological samples collected at baseline and after the intervention are used for exploratory mechanistic analyses.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Castille and León
-
Aranda de Duero, Castille and León, Espanha
- Hospital Santos Reyes
-
Burgos, Castille and León, Espanha, 09006
- Hospital Universitario de Burgos
-
Soria, Castille and León, Espanha
- Hospital Santa Bárbara
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age ≥70 years.
- Confirmed diagnosis of transthyretin cardiac amyloidosis (TTR-CA) based on positive bone scintigraphy with diphosphonates (Perugini grade 2 or 3) and absence of monoclonal protein.
- Clinical stability during the 4 weeks prior to enrollment.
- Ability to understand the study procedures and provide written informed consent.
Exclusion Criteria:
- Light-chain (AL) amyloidosis or other non-TTR amyloidosis variants.
- Absolute medical contraindication to moderate-intensity exercise.
- Severe comorbid conditions with an estimated life expectancy <6 months.
- Severe cognitive impairment (Mini-Mental State Examination score <20).
- Concurrent participation in another clinical trial or structured exercise program.
- Known allergy or intolerance to creatine, beta-hydroxy-beta-methylbutyrate (HMB), or microcrystalline cellulose.
- Severe renal impairment requiring dialysis.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Usual Care
Participants received usual medical care for transthyretin cardiac amyloidosis, including routine cardiology follow-up and general lifestyle and nutritional recommendations, without the structured study exercise program or study supplementation. |
Standard clinical management for transthyretin cardiac amyloidosis according to routine cardiology practice. |
|
Comparador de Placebo: Exercise + Microcrystalline Cellulose Control Supplementation
Participants performed a 12-week home-based multicomponent exercise program and received daily microcrystalline cellulose as the control supplement. The supplement was provided in sachets matched to the supplementation procedure used in the experimental arm. |
A 12-week home-based multicomponent exercise program adapted from the Vivifrail model, including strength, balance, mobility, and endurance exercises tailored to individual functional capacity. Daily oral supplementation with microcrystalline cellulose, used as a nutritionally inert control supplement to match supplementation procedures. |
|
Experimental: Exercise + Creatine and HMB Supplementation
Participants performed the same 12-week home-based multicomponent exercise program and received daily supplementation with creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day). |
A 12-week home-based multicomponent exercise program adapted from the Vivifrail model, including strength, balance, mobility, and endurance exercises tailored to individual functional capacity. Daily oral supplementation with creatine monohydrate (3 g/day) and β-hydroxy-β-methylbutyrate (HMB, 3 g/day) for 12 weeks. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Handgrip Strength
Prazo: Baseline and 12 weeks
|
Change in maximal isometric handgrip strength measured in kilograms (kg) using a calibrated handheld dynamometer (best of three attempts for the dominant hand), expressed as the difference between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in 6-Minute Walk Test Distance
Prazo: Baseline and 12 weeks
|
Change in walking capacity assessed by the 6-minute walk test, measured as the difference in total distance walked (meters) between baseline and 12 weeks. |
Baseline and 12 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Fat Mass
Prazo: Baseline and 12 weeks
|
Change in total body fat mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in Skeletal Muscle Mass
Prazo: Baseline and 12 weeks
|
Change in skeletal muscle mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in Fat-Free Mass
Prazo: Baseline and 12 weeks
|
Change in fat-free mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in Phase Angle
Prazo: Baseline and 12 weeks
|
Change in phase angle measured in degrees (°) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in Frailty Status Assessed by the FRAIL Scale
Prazo: Baseline and 12 weeks
|
Change in frailty status assessed by the FRAIL scale, a 5-item questionnaire with scores ranging from 0 to 5, where higher scores indicate greater frailty, expressed as the difference between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in Short Physical Performance Battery (SPPB) Score
Prazo: Baseline and 12 weeks
|
Change in Short Physical Performance Battery (SPPB) total score, ranging from 0 to 12 points, where higher scores indicate better physical performance, expressed as the difference between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in Clinical Frailty Scale (CFS) Score
Prazo: Baseline and 12 weeks
|
Change in frailty severity assessed by the Clinical Frailty Scale (CFS), a 9-point ordinal scale ranging from 1 (very fit) to 9 (terminally ill), where higher scores indicate greater frailty. |
Baseline and 12 weeks
|
|
Change in Barthel Index Score
Prazo: Baseline and 12 weeks
|
Change in functional independence assessed by the Barthel Index, scored from 0 to 100, where higher scores indicate greater independence. |
Baseline and 12 weeks
|
|
Change in SARC-F Score
Prazo: Baseline and 12 weeks
|
Change in sarcopenia risk assessed by the SARC-F questionnaire, with scores ranging from 0 to 10, where higher scores indicate greater sarcopenia risk. |
Baseline and 12 weeks
|
|
Change in Minnesota Living With Heart Failure Questionnaire Score
Prazo: Baseline and 12 weeks
|
Change in health-related quality of life assessed by the Minnesota Living With Heart Failure Questionnaire (MLHFQ), with total scores ranging from 0 to 105, where higher scores indicate worse quality of life. |
Baseline and 12 weeks
|
|
Change in Charlson Comorbidity Index
Prazo: Baseline and 12 weeks
|
Change in comorbidity burden assessed using the Charlson Comorbidity Index, a weighted index that accounts for the number and severity of comorbid conditions, where higher scores indicate greater comorbidity burden. |
Baseline and 12 weeks
|
|
Exercise Program Adherence
Prazo: Up to 12 weeks
|
Proportion (%) of prescribed exercise sessions completed, with adequate adherence defined as completion of at least 80% of prescribed sessions. |
Up to 12 weeks
|
|
Supplement Adherence
Prazo: Up to 12 weeks
|
Proportion (%) of planned supplement doses consumed, with optimal compliance defined as 90-110%. |
Up to 12 weeks
|
|
Change in Mini Nutritional Assessment Short-Form (MNA-SF) Score
Prazo: Baseline and 12 weeks
|
Change in nutritional status assessed by the Mini Nutritional Assessment Short-Form (MNA-SF), with scores ranging from 0 to 14 points, where lower scores indicate poorer nutritional status and greater risk of malnutrition. |
Baseline and 12 weeks
|
|
Incidence of Intervention-Related Adverse Events
Prazo: Up to 12 weeks
|
Number and type of adverse events related to exercise and/or supplementation, classified according to severity and relatedness, collected during the 12-week intervention period. |
Up to 12 weeks
|
|
Rate of Supplement Discontinuation
Prazo: Up to 12 weeks
|
Proportion of participants who discontinue study supplementation during the intervention period. |
Up to 12 weeks
|
|
Change in Skeletal Muscle Index (SMI)
Prazo: Baseline and 12 weeks
|
Change in skeletal muscle index (SMI), expressed as skeletal muscle mass normalized to height squared (kg/m²), measured using multifrequency bioelectrical impedance analysis, between baseline and 12 weeks. |
Baseline and 12 weeks
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Growth Differentiation Factor 15 (GDF-15)
Prazo: Baseline and 12 weeks
|
Change in serum GDF-15 concentration (ng/mL) measured by immunoassay. |
Baseline and 12 weeks
|
|
Change in Soluble ST2
Prazo: Baseline and 12 weeks
|
Change in serum soluble ST2 concentration (ng/mL) measured by immunoassay. |
Baseline and 12 weeks
|
|
Change in Interleukin-6 (IL-6)
Prazo: Baseline and 12 weeks
|
Change in serum interleukin-6 (IL-6) concentration (pg/mL) measured by immunoassay. |
Baseline and 12 weeks
|
|
Change in C-Reactive Protein (CRP)
Prazo: Baseline and 12 weeks
|
Change in serum C-reactive protein (CRP) concentration (mg/dL) measured by immunoassay. |
Baseline and 12 weeks
|
|
Change in circulating miR-21 expression
Prazo: Baseline and 12 weeks
|
Change in circulating miR-21 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt). |
Baseline and 12 weeks
|
|
Change in circulating miR-29 expression
Prazo: Baseline and 12 weeks
|
Change in circulating miR-29 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt). |
Baseline and 12 weeks
|
|
Change in circulating miR-34a expression
Prazo: Baseline and 12 weeks
|
Change in circulating miR-34a expression measured by quantitative PCR, expressed as relative expression (ΔΔCt). |
Baseline and 12 weeks
|
|
Change in circulating miR-155 expression
Prazo: Baseline and 12 weeks
|
Change in circulating miR-155 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt). |
Baseline and 12 weeks
|
|
Change in PBMC Immune Polarization Profile by Flow Cytometry
Prazo: Baseline and 12 weeks
|
Change in the immunophenotypic profile of peripheral blood mononuclear cells (PBMCs) assessed by multiparametric flow cytometry, including the relative abundance of cell populations with M1-like and M2-like phenotypes and their ratio. |
Baseline and 12 weeks
|
|
Change in Pro-inflammatory (M1) Gene Expression Markers
Prazo: Baseline and 12 weeks
|
Change in gene expression of predefined pro-inflammatory (M1-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt). |
Baseline and 12 weeks
|
|
Change in Anti-inflammatory (M2) Gene Expression Markers
Prazo: Baseline and 12 weeks
|
Change in gene expression of predefined anti-inflammatory/regenerative (M2-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt). |
Baseline and 12 weeks
|
|
Change in Serum Albumin
Prazo: Baseline and 12 weeks
|
Change in serum albumin concentration (g/dL) between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in Serum Prealbumin
Prazo: Baseline and 12 weeks
|
Change in serum prealbumin concentration (g/dL) between baseline and 12 weeks |
Baseline and 12 weeks
|
|
Change in Vitamin D
Prazo: Baseline and 12 weeks
|
Change in serum 25-hydroxyvitamin D concentration (ng/mL) between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in Galectin-3
Prazo: Baseline and 12 weeks
|
Change in serum galectin-3 concentration (ng/mL) between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in NT-proBNP
Prazo: Baseline and 12 weeks
|
Change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration (pg/mL) between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in High-Sensitivity Troponin T
Prazo: Baseline and 12 weeks
|
Change in serum high-sensitivity cardiac troponin T concentration (ng/L) between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in Leptin
Prazo: Baseline and 12 weeks
|
Change in serum leptin concentration (ng/mL) between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in Adiponectin
Prazo: Baseline and 12 weeks
|
Change in serum adiponectin concentration (µg/mL) between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in IGF-1
Prazo: Baseline and 12 weeks
|
Change in serum insulin-like growth factor 1 (IGF-1) concentration (ng/mL) between baseline and 12 weeks. |
Baseline and 12 weeks
|
|
Change in Klotho
Prazo: Baseline and 12 weeks
|
Change in serum Klotho concentration (pg/mL) between baseline and 12 weeks. |
Baseline and 12 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Juan Mielgo-Ayuso, PhD, Universidad de Burgos
- Investigador principal: José A Pérez Rivera, PhD, MD, Hospital Universitario de Burgos
Publicações e links úteis
Publicações Gerais
- Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jul 1;48(4):601. doi: 10.1093/ageing/afz046. No abstract available.
- de Souto Barreto P, Rolland Y, Vellas B, Maltais M. Association of Long-term Exercise Training With Risk of Falls, Fractures, Hospitalizations, and Mortality in Older Adults: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019 Mar 1;179(3):394-405. doi: 10.1001/jamainternmed.2018.5406.
- Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072.
- Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003.
- Ramos-Hernandez R, Miguel-Ortega A, Martinez-Ferran M, Fernandez-Lazaro D, Busto N, Mielgo-Ayuso J. Combined creatine and HMB co-supplementation improves functional strength independent of muscle mass in physically active older adults: a randomized crossover trial. Geroscience. 2026 Jun;48(3):4457-4475. doi: 10.1007/s11357-025-01889-y. Epub 2025 Oct 10.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Processos Patológicos
- Doenças Neuromusculares
- Metabolismo, Erros Inatos
- Doenças Genéticas, Congênitas
- Doenças Metabólicas
- Doenças do Sistema Nervoso Periférico
- Doenças Neurodegenerativas
- Distúrbios Heredodegenerativos, Sistema Nervoso
- Deficiências de Proteostase
- Neuropatias Amilóides
- Amiloidose Familiar
- Amiloidose
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Condições Patológicas, Sinais e Sintomas
- Doenças Nutricionais e Metabólicas
- Fragilidade
- Neuropatias Amilóides Familiares
- Aminoácidos, peptídeos e proteínas
- Produtos químicos orgânicos
- Aminoácidos
- Guanidinas
- Amidines
- Creatina
Outros números de identificação do estudo
- EFICAC-TTR-UBU-HUBU
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified individual participant data that underlie the results reported in publications will be made available upon reasonable request.
Prazo de Compartilhamento de IPD
Beginning 6 months after publication and ending 5 years after publication.
Critérios de acesso de compartilhamento IPD
Access to de-identified individual participant data will be granted upon reasonable request to the principal investigator. Requests must include a methodologically sound research proposal and will be evaluated for scientific merit and feasibility. Data sharing will require the execution of a data sharing agreement and will comply with applicable data protection and privacy regulations.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .